Form 8-K - Current report:
SEC Accession No. 0001213900-25-023220
Filing Date
2025-03-12
Accepted
2025-03-12 16:20:08
Documents
15
Period of Report
2025-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0234060-8k_nektar.htm   iXBRL 8-K 24685
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER 2024 FINANCIAL ea023406001ex99-1_nektar.htm EX-99.1 88856
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2044
  Complete submission text file 0001213900-25-023220.txt   301328

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20250312.xsd EX-101.SCH 3009
5 XBRL LABEL FILE nktr-20250312_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE nktr-20250312_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0234060-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 25732014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)